Selected highlights in the updated treatment of hypertension

Daniel Creegan1, John W McEvoy2

  • 1University Hospital Galway and SAOLTA University Health Care Group, Galway, Ireland; School of Medicine, University of Galway, Ireland.

PubMed

Insights

This review highlights recent advances in hypertension management, including lower blood pressure targets, renal denervation efficacy, salt intake insights, and the benefits of multidisciplinary care for cardiovascular disease prevention.

Area of Science:

  • Cardiology
  • Nephrology
  • Public Health

Background:

  • Hypertension is a primary global risk factor for cardiovascular disease and mortality.
  • Despite available treatments, hypertension is frequently underdiagnosed and undertreated.
  • Effective management strategies are crucial for reducing cardiovascular events.

Purpose of the Study:

  • To provide a concise update on recent developments in hypertension management.
  • To highlight key areas for clinical consideration in treating hypertension.
  • To inform clinicians about emerging evidence and therapeutic approaches.

Main Methods:

  • Review of recent scientific literature and clinical studies.
  • Synthesis of evidence on novel treatment targets and interventions.
  • Analysis of data related to dietary factors and care models.

Main Results:

  • Evidence supports lower systolic blood pressure (BP) treatment targets.
  • Renal denervation shows promise in specific hypertensive populations.
  • New data informs the ongoing debate on dietary salt intake.
  • Multidisciplinary care models demonstrate significant potential for improved outcomes.

Conclusions:

  • Lowering systolic BP targets is strongly motivated by new evidence.
  • Renal denervation warrants further investigation for hypertension management.
  • Dietary salt reduction remains a critical public health consideration.
  • Integrating multidisciplinary care can optimize hypertension control and reduce cardiovascular risk.

Related Concept Videos

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists01:18

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
171
Antihypertensive Drugs: Action of Diuretics01:16

Antihypertensive Drugs: Action of Diuretics

Diuretics are antihypertensive drugs used to treat hypertension resulting from sodium and water retention. Sodium, vital for fluid balance and nerve or muscle function, is regulated by the kidneys through millions of nephrons. Blood enters nephrons via afferent arterioles, which branch into capillaries called glomeruli. These filter blood plasma, allowing water and solutes, like sodium ions, to pass through capillary walls into Bowman's capsule. The filtrate then flows through various...
789
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
436
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers01:26

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
176
Hypertension and Regulation of Blood Pressure01:18

Hypertension and Regulation of Blood Pressure

Hypertension, the most common cardiovascular disease, is diagnosed through repeated measurements of elevated blood pressure. Its risks, including damage to the kidney, heart, and brain, are directly proportional to blood pressure levels. Starting from 115/75 mm Hg, the risk of cardiovascular disease doubles with each increment of 20/10 mm Hg. The diagnosis relies on blood pressure measurements, not on patient symptoms, as hypertension is often asymptomatic until end-organ damage is imminent or...
2.1K
Alterations in Blood Pressure01:30

Alterations in Blood Pressure

Alterations in blood pressure, such as hypertension (high blood pressure) and hypotension (low blood pressure), significantly affect human health. Understanding these conditions' classifications, causes, and symptoms is essential for effective management and treatment.
Hypertension (High blood pressure)
Hypertension occurs when blood pressure readings consistently exceed the normal range. It is diagnosed when systolic blood pressure (the top number, indicating pressure while the heart...
1.2K